Role of topical tofacitinib in autoimmune skin disorders: An expert opinion

---

Review Article

Author Details : Kiran Godse*, Mukesh Girdhar, Soumya Jagadeesan, Ritu Laiker

Volume : 10, Issue : 3, Year : 2024

Article Page : 254-259

https://doi.org/10.18231/j.ijced.2024.045

Suggest article by email

Get Permission

---

Abstract

Autoimmune skin diseases, caused by immune system dysfunctions, have complex mechanisms. Biologicals are widely used to treat these chronic conditions. These available treatments for autoimmune skin diseases have several drawbacks, including related adverse effects, issues with adherence to long-term therapy, and the need for better management strategies. Recently, JAK inhibitors, like tofacitinib, have shown promise in treating vitiligo, alopecia areata (AA), atopic dermatitis (AD), and psoriasis, among other autoimmune dermatological conditions. Conventional systemic therapies require monitoring for adverse events (AEs) and risk of drug interactions, thus resulting in reduced compliance. Topical JAK inhibitors have a superior safety profile due to low systemic absorption, provide tailored therapy, and limited systemic effects. Topical tofacitinib is being investigated for off-label autoimmune dermatological disorders and has shown promising outcomes. According to the opinion of the experts, topical tofacitinib (2%), twice daily (BID), is suggested as an effective treatment for autoimmune skin diseases with minimal AEs.
 
Keywords: Autoimmune skin diseases, JAK, Topical, Tofacitinib, Alopecia areata, vitiligo, Atopic dermatitis, Psoriasis, Expert opinion

How to cite : Godse K, Girdhar M, Jagadeesan S, Laiker R, Role of topical tofacitinib in autoimmune skin disorders: An expert opinion. IP Indian J Clin Exp Dermatol 2024;10(3):254-259

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.